From: Sublingual immunotherapy: World Allergy Organization position paper 2013 update
Author, year design | Ages (y) | Treat-ment | Dropouts | Allergen | Duration | Cumulative doses | Disease | Main results |
---|---|---|---|---|---|---|---|---|
Eifan, 2010 [27] | 5–12 | 16 SCIT | 2 | Mite | 1 y | SCIT 111 mg Der p 1/156 mg Der f 1 | RA | Significant reduction of total rhinitis and asthma score, medication score, VAS, and skin reactivity P < 0.05 versus pharmacotherapy for both SCIT and SLIT. No difference between routes of administration. |
Randomized, open, controlled | 16 SLIT | 1 | ||||||
16 CON | 2 | |||||||
SLIT 295.5 mg Der p 1/f 1 | ||||||||
Keles, 2011 [24] | 5–12 | 15 SCIT | 2 | Mite | 18 mo | Der p 1: 53 mcg SLIT and 42 mcg SCIT | A | Decreased asthma attacks and use of steroids at 4, 12, 18 mo for SCIT and SCIT+SLIT, at 12 mo only for SLIT. No change in VAS for asthma with SCIT or SIT alone. |
Double blind, double dummy, controlled | 15 SLIT | 2 | ||||||
15 SLIT | 1 | |||||||
+ SCIT | ||||||||
15 CON | 3 | |||||||
Yukselen, 2012 [62] | 7–14 | 10 SCIT | 1 | Mite | 1 y | 173,733 TU (86,866.5 TU D pt. and 86,866.5 TU Df). | RA | Significant reduction in symptom and medication score versus baseline with both treatments. SCIT better than SLIT versus placebo. |
10 SLIT | 1 | |||||||
Double blind, double dummy, placebo controlled | ||||||||
10 PLA | 0 |